Search
forLearn
5 / 801 resultslearn PP405
mitochondrial pyruvate carrier (MPC) inhibitor by Pelage in early trials
learn Ensete ventricosum
learn Oxytocin
learn Betamethasone Dipropionate
Research
5 / 382 results
research Comparing the risk of adverse pregnancy outcomes of Chinese patients with polycystic ovary syndrome with and without antiandrogenic pretreatment
Women with PCOS who had antiandrogenic treatment before pregnancy had fewer complications than those without treatment.
research The Utility of Metformin Therapy in Reproductive-Aged Women with Polycystic Ovary Syndrome (PCOS)
Metformin helps regulate menstrual cycles, induce ovulation, and improve pregnancy outcomes in women with PCOS.
research Appropriate use of metformin in early pregnancy: is there a role for first trimester use?
Metformin is safe in early pregnancy for women with PCOS and may reduce certain risks.
research Liposomes with an Ethanol Fraction as an Application for Drug Delivery
Ethosomes improve drug delivery through the skin but may have side effects like irritation.
research A focus on important reproductive health care issues – cancer, urinary incontinence and the consequences of pre‐term birth
The issue covers reproductive health topics like cancer markers, incontinence treatments, and the impact of pre-term birth.
Community Join
5 / 1000+ resultscommunity Pyrilutamide - your experience?
The conversation is about the lack of improvement in hair loss after using Pyrilutamide for 14 weeks, with the original poster unable to use Finasteride due to depression. Replies suggest that Pyrilutamide, like RU58841, may not work for everyone, and a more potent drug is being developed by Kintor.
community Pelage have presented only phase 2a. The rest of phase 2 for PP405 will be presented at a later medical meeting
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.
community New company created by Dr. Kang-Yell Choi to commercialize PTD-DBM therapy
PTD-DBM therapy for hair loss is being developed by Dr. Kang-Yell Choi, with human testing planned in South Korea. Some clinics in the U.S. offer PTD-DBM/valproic acid therapy, but it hasn't completed trials yet.
community People are misunderstanding PP405. 31% response at 8 weeks is better than you think
PP405 shows promise as a hair loss treatment, with 31% experiencing increased hair density in a short trial. It may complement treatments like finasteride and minoxidil, but long-term effectiveness and safety need confirmation.
community PP405 bandwagon, time to resume the hype train.
PP405 shows promise in hair regrowth, potentially outperforming existing treatments like finasteride and minoxidil, with significant results in just four weeks. The treatment is still in early stages, with further trials needed to determine its long-term effectiveness and optimal dosage.